Chronic obstructive pulmonary disease (COPD) is characterized by progressive and minimally reversible airflow limitation with systemic inflammation, which can be prevented and treated. Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methlglutaryl coenzyme A(HMG-CoA) reductase, and have an established role in the treatment of cardiovascular diseases. Recent studies have revealed that statins have profound anti-inflammatory effects by reducing induction of matrix metalloproteinase, expression of cytokines and cell adhesion molecules, antioxidant state and C-reactive protein, which decreases lung function deterioration, morbidity and mortality in COPD.